Variables | Immunological status | COR (95% CI) | AOR (95% CI) | ||
---|---|---|---|---|---|
Favorable immunological status | Unfavorable immunological status | ||||
Baseline BMI (kg/m2) | < 18.5 | 65 (46.8) | 74 (53.2) | 1.00 | - |
≥ 18.5 | 106 (57.6) | 78 (42.4) | 1.55 (0.99, 2.41) | - | |
Baseline WHO stage | Stages I & II | 57 (64.8) | 31 (35.2) | 2.42 (1.16, 5.07) | - |
Stage III | 95 (49.7) | 96 (50.3) | 1.30(0.67, 2.52) | - | |
Stage IV | 19 (43.2) | 25 (56.8) | 1.00 | - | |
Duration since ART initiation (year) | 1–5 | 48 (49.5) | 49 (50.5) | 1.05 (0.55, 2.00) | - |
6–10 | 78 (51.7) | 73 (48.3) | 0.68 (0.54, 1.12) | - | |
> 10 | 45 (60) | 30 (40) | 1.00 | - | |
Baseline CD4 count (cell/mm3) | < 200 | 69 (39.2) | 107 (60.8) | 1.00 | 1.00 |
200–499 | 70 (63.1) | 41 (36.9) | 2.65 (1.62, 4.32) | 2.7 (1.58, 4.62)* | |
> 499 | 32 (88.9) | 4 (11.1) | 12.61 (4.20, 36.63) | 9.59 (3.06, 30.07)* | |
Patient address | Urban | 139 (56.3) | 108 (43.7) | 1.77 (1.05, 2.98) | 1.90 (1.05, 3.43)* |
Rural | 32 (42.1) | 44 (57.9) | 1.00 | 1.00 | |
Current age (year) | ≤ 30 | 39 (66.1) | 20 (33.9) | 2.04 (1.04, 4.01) | - |
31–45 | 87 (50.6) | 85 (49.4) | 1.07 (0.64, 1.77) | - | |
> 45 | 45 (48.9) | 47 (51.1) | 1.00 | - | |
Age at enrollment (year) | ≤ 25 | 52 (64.2) | 29 (35.8) | 1.30 (0.65, 2.61) | 0.59 (0.17, 2.10) |
26–40 | 86 (46.5) | 99 (53.5) | 0.63 (0.35, 1.15) | 0.53 (0.15, 0.83)* | |
> 40 | 33 (57.9) | 24 (42.1) | 1.00 | 1.00 |